the Application of an Electronic Nose in the Early detection of Aspergillosis II

the Application of an Electronic Nose in the Early detection of Aspergillosis II - The AENEAS II study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39283

Enrollment

150

Registered

2012-11-19

Start date

2012-12-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspergillosis Invasive Pulmonary Aspergillosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - aged 18 years or older; - diagnosed with a hematological malignancy; - treatment is expected to result in prolonged (>7 days) neutropenia (

Exclusion criteria

Exclusion criteria: - Patients are unable to perform the breathing manouevre needed for eNose-analysis of exhaled air

Design outcomes

Primary

Measure	Time frame
Exhaled molecular profiles (by eNose and GC-MS) and the accuracy with which serial analysis of these profiles can discriminate between patients with probable or proven invasive pulmonary aspergillosis and neutropenic controls in terms of sensitivity, specificity and accuracy of the predictive algorithm.	—

Secondary

Measure	Time frame
1. Individual biomarkers and proteomic profiles in BAL fluid, exhaled air and serum predictive for invasive pulmonary aspergillosis, determined by different mass spectrometry techniques. 2. The alteration in the distribution of the pulmonary microbial community in neutropenic subjects developing invasive pulmonary aspergillosis compared to neutropenic subjects who do not.	—

Countries

Netherlands

Outcome results